nature portfolio

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed	
☐	☒	The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒	The statistical test(s) used AND whether they are one- or two-sided *Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
☐	☒	A description of all covariates tested
☐	☒	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒	For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted *Give P values as exact values whenever suitable.*
☒	☐	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐	Estimates of effect sizes (e.g. Cohen's *d*, Pearson's *r*), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection	iCys 7.0 software for Windows XP
Data analysis	iCys 7.0 software for Windows XP, Image J software, CellProfiler 2.2.0 software, Galaxy platform (EU server: usegalaxy.eu), MaxQuant 1.6.2.10 software, QuickFit 3.0 software, SymPhoTime64 software

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The Whole Genome Sequencing datasets generated during the current study are available in the NCBI SRA repository, under the BioProject accession number PRJNA853352 [https://www.ncbi.nlm.nih.gov/sra/PRJNA853352], WGS BioSample accession numbers (SAMN29379375-78 and SAMN42397447-48). Microarray datasets were deposited into GEO database under accession number GSE225680 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225680]. The RNA-seq

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	*Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data where this information has been collected, and consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.*
Population characteristics	*Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."*
Recruitment	*Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.*
Ethics oversight	*Identify the organization(s) that approved the study protocol.*

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	In LSC experiments, the number of analyzed G1 nuclei was between 200-2000/well, out of the about 500-5000 events scanned. Box-and-whisker plots of colocalization and texture analyses were created from the data of 20-30 nuclei.
Data exclusions	In LSC measurements, aggregates and cell debris were excluded from analyses by gating.
Replication	LSC and confocal experimental results were based at least three independent experiments. The FCS measurements shown were reproduced once on the same reconstituted nucleosome sample. Whole genome sequencing was performed twice for each treated sample.
Randomization	In LSC experiments, the scanning area containing 500-5000 events was selected in the middle of the wells.
Blinding	In view of the controls applied and the several different approaches followed, efforts toward blinding were not undertaken.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	*Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).*
Research sample	*State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.*

Sampling strategy	*Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.*
Data collection	*Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.*
Timing	*Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.*
Data exclusions	*If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.*
Non-participation	*State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.*
Randomization	*If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.*

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	*Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.*
Research sample	*Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.*
Sampling strategy	*Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.*
Data collection	*Describe the data collection procedure, including who recorded the data and how.*
Timing and spatial scale	*Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken*
Data exclusions	*If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.*
Reproducibility	*Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.*
Randomization	*Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.*
Blinding	*Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.*

Did the study involve field work? ☐ Yes ☐ No

Field work, collection and transport

Field conditions	*Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).*
Location	*State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).*
Access & import/export	*Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).*

| | Disturbance | *Describe any disturbance caused by the study and how it was minimized.* |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern

Methods

n/a	Involved in the study
☐	☒ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used	rabbit polyclonal anti-H2A.Z (ab97966 (ZAbA), lot num.: GR90761-2, GR90761-6, GR90761-8, GR90761-12, GR90761-13, GR90761-15, ab4174, lot num.: 1015872-1, 1058382-2, Abcam, Cambridge, UK; 1 mg/ml), sheep polyclonal anti-H2A.Z (acetyl K4+K7 +K11, ab18262, lot num.: GR306397-1, Abcam, Cambridge, UK; 0.5 mg/ml), rabbit polyclonal anti-H2A.Z (PA5-17336 (ZAbB), lot num.: VH3053562, XK3767973, UB2712502, VC2958177, Thermo Fisher Scientific, Waltham, Massachusetts, USA; 62 µg/ml), rabbit polyclonal anti-H2A.Z (07-594, lot num.: 3946459, Merck-Millipore, Darmstadt, Germany), rabbit polyclonal anti-PWWP2A (NBP2-13833, lot num.: A106444, Novus Biologicals, Centennial, Colorado, USA; 0.2 mg/ml), rabbit polyclonal anti-H2A.X (ab11175, Abcam, Cambridge, UK; 1 mg/ml), rabbit polyclonal anti-H2A (ab18255, lot num.: GR3211735-2, Abcam, Cambridge, UK; 1 mg/ml), rabbit polyclonal anti-H2B (ab52484, lot num.: GR3232535-3, GR3173752-4, GR163233-5, Abcam, Cambridge, UK; 1 mg/ml), mouse monoclonal anti-H1 (ab71594, clone name: AE-4, lot num.: GR159309-23, Abcam, Cambridge, UK; 1 mg/ml), mouse monoclonal anti-HP1 (ab234085, clone name: 3A11F8, lot num.: GR3241506-8, Abcam, Cambridge, UK; 1 mg/ml), rabbit polyclonal anti-Lamin B1 (ab16048, lot num.: GR3188003-1, Abcam, Cambridge, UK; 0.1-1 mg/ml), rabbit polyclonal anti-Rad21 (ab992, lot num.: GR-3235714-1, Abcam, Cambridge, UK; 0.2-1 mg/ml), rabbit polyclonal anti-CTCF (ab70303, lot num.: GR3218438-2, Abcam, Cambridge, UK; 0.2 mg/ml) mouse monoclonal anti-γH2A.X (05-636, clone name: JBW301, Merck-Millipore, Darmstadt, Germany), mouse monoclonal anti-H3K4me3 (74; clone name: CMA304, lot num.: 16H10, 0,5 mg/ml), rabbit polyclonal anti-H3K9me3 (ab8889, lot num.: 699686 , Abcam, Cambridge, UK; 0.2-1 mg/ml) mouse monoclonal anti-H3K9me3 (74; clone name: CMA318, lot num.: 2F3 0,5 mg/ml) or mouse monoclonal anti-H3K27me3 (75; clone name: CMA323, lot num.: 1E7 0,5 mg/ml)
Validation	H2A.Z antibodies were validated in siRNA experiments and in western blot experiments using recombinant H2A and H2A.Z histones

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

Cell line source(s)	HeLa cells expressing H2B-GFP and H3-GFP fusion proteins were from Dr. Hiroshi Kimura's lab, HeLa cells expressing GFP-H2A.Z fusion protein were from Dr. H. T. Marc Timmers's lab. Wild type, H2A.Z.1 knock-out, H2A.Z.2 knock-out and mutant (5KR and ΔC) H2A.Z.1 expressing double knock-out DT-40 chicken B cells provided by Dr. Masahiko Harata. WM35 and MEL1617 melanoma cell lines (purchased from Coriell Institute for Medical Researche respectively) were provided by Dr. Margit Balázs, University of Debrecen.
Authentication	Authentication was based on communication with the providers. Melanoma cells (MEL1617, WM35) were identified based on RNA-seq data obtained for the two cell lines in our lab.
Mycoplasma contamination	The cell lines used were negative for mycoplasma.
Commonly misidentified lines (See ICLAC register)	Not applicable.

Palaeontology and Archaeology

Specimen provenance	*Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information). Permits should encompass collection and, where applicable, export.*
Specimen deposition	*Indicate where the specimens have been deposited to permit free access by other researchers.*

| Dating methods | *If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.* |

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

| Ethics oversight | *Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.* |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

| Laboratory animals | *For laboratory animals, report species, strain and age OR state that the study did not involve laboratory animals.* |

| Wild animals | *Provide details on animals observed in or captured in the field; report species and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.* |

| Reporting on sex | *Indicate if findings apply to only one sex; describe whether sex was considered in study design, methods used for assigning sex. Provide data disaggregated for sex where this information has been collected in the source data as appropriate; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex-based analyses where performed, justify reasons for lack of sex-based analysis.* |

| Field-collected samples | *For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.* |

| Ethics oversight | *Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.* |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

| Clinical trial registration | *Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.* |

| Study protocol | *Note where the full trial protocol can be accessed OR if not available, explain why.* |

| Data collection | *Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.* |

| Outcomes | *Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.* |

Dual use research of concern

Policy information about dual use research of concern

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No | Yes
☐ ☐ Public health
☐ ☐ National security
☐ ☐ Crops and/or livestock
☐ ☐ Ecosystems
☐ ☐ Any other significant area

Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes	
☐	☐	Demonstrate how to render a vaccine ineffective
☐	☐	Confer resistance to therapeutically useful antibiotics or antiviral agents
☐	☐	Enhance the virulence of a pathogen or render a nonpathogen virulent
☐	☐	Increase transmissibility of a pathogen
☐	☐	Alter the host range of a pathogen
☐	☐	Enable evasion of diagnostic/detection modalities
☐	☐	Enable the weaponization of a biological agent or toxin
☐	☐	Any other potentially harmful combination of experiments and agents

ChIP-seq

Data deposition

☒ Confirm that both raw and final processed data have been deposited in a public database such as GEO.

☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links	https://www.ncbi.nlm.nih.gov/sra/PRJNA853352

May remain private before publication.

Files in database submission	H3K9me3 Cut&Run-seq (without MNAse pretreatment) on untreated HeLa cells no antibody control (SRR29767617) H3K9me3 Cut&Run-seq (without MNAse pretreatment) on untreated HeLa cells (SRR29767614) H3K9me3 Cut&Run-seq (without MNAse pretreatment) on SCR treated HeLa cells (SRR29767615) H3K9me3 Cut&Run-seq (without MNAse pretreatment) on C9 treated HeLa cells (SRR29767616) H3K4me3 Cut&Run-seq (without MNAse pretreatment) using CMA304 antibody on untreated HeLa cells (SRR29767618) H3K4me3 Cut&Run-seq (without MNAse pretreatment) using CMA304 antibody on SCR treated HeLa cells (SRR29767619) H3K4me3 Cut&Run-seq (without MNAse pretreatment) using CMA304 antibody on C9 treated HeLa cells (SRR29767620) H3K9me3 Cut&Run-seq (with MNAse pretreatment) on untreated HeLa cells (SRR29767625) H3K9me3 Cut&Run-seq (with MNAse pretreatment) on SCR treated HeLa cells (SRR29767626) H3K4me3 Cut&Run-seq (without MNAse pretreatment) no antibody control on HeLa cells (SRR29767627) H3K9me3 Cut&Run-seq (with MNAse pretreatment) on C9 treated HeLa cells (SRR29767629) No antibody control of Cut&Run-seq (with MNAse pretreatment) on SCR treated HeLa cells (SRR29767630) H3K9me3 Cut&Run-seq (with MNAse pretreatment) on SCR treated HeLa cells (SRR29767631) H3K4me3 Cut&Run-seq (with MNAse pretreatment) on SCR treated HeLa cells (SRR29767632) No antibody control of Cut&Run-seq (with MNAse pretreatment) on untreated HeLa cells (SRR29767636) H3K9me3 Cut&Run-seq (with MNAse pretreatment) on untreated HeLa cells (SRR29767633) H3K4me3 Cut&Run-seq (with MNAse pretreatment) on untreated HeLa cells (SRR29767634) No antibody control of Cut&Run-seq (with MNAse pretreatment) on C9 treated HeLa cells (SRR29767635) H3K9me3 Cut&Run-seq (with MNAse pretreatment) on C9 treated HeLa cells (SRR29767637) H3K4me3 Cut&Run-seq (with MNAse pretreatment) on C9 treated HeLa cells (SRR29767638) H3K4me3 Cut&Run-seq (without MNAse pretreatment) using Abcam antibody on HeLa cells (SRR29767639) H3K4me3 Cut&Run-seq (without MNAse pretreatment) using CMA304 antibody on HeLa cells (SRR29767640)

Genome browser session (e.g. UCSC)	*Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.*

Methodology

Replicates	2
Sequencing depth	Whole genome sequencing: 30x coverage (320 million reads per sample, 150bp paired end sequencing). CUT&RUN: 30-40 million (75 bp long single-end) reads per sample were generated by NextSeq 500 sequencer (Illumina) and were aligned to the hg19 reference genome using the BWA tool.
Antibodies	CUT&RUN: mouse monoclonal anti-H3K4me3 (74; clone name: CMA304, lot num.: 16H10, 0,5 mg/ml), rabbit polyclonal anti-H3K9me3 (ab8889, lot num.: 699686 , Abcam, Cambridge, UK; 0.2-1 mg/ml)
Peak calling parameters	CUT&RUN: Peaks were called using SEACR1.3 (Galaxy version) using the "relaxed" parameter and the 'norm' option.
Data quality	Reads were quality controlled by FastQC software. The total number of peaks were between 15000 and 40000 per sample.
Software	Analyses of the Whole Genome Sequencing and CUT&RUN data was performed on the Galaxy platform (EU server: usegalaxy.eu) , BWA-MEM, Samtools, BamCompare (deeptools package), PlotCoverage (deeptools).

Flow Cytometry

Plots

Confirm that:

☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

☐ All plots are contour plots with outliers or pseudocolor plots.

☐ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Live HeLa cells were treated with SBECD/C9 or C6 peptide complex for different time points (peptides were conjugated with carboxyfluorescein). After trypsinization live cells were kept on ice, in ice cold PBS buffer until measurement.
Instrument	Becton Dickinson FACS Calibur
Software	CellQuest software for data collection, ReFlex software for analyses.
Cell population abundance	10 000 cells were collected from each sample.
Gating strategy	Gating was performed on a FSC vs. SSC dot plot.

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type	*Indicate task or resting state; event-related or block design.*
Design specifications	*Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.*
Behavioral performance measures	*State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).*

Acquisition

Imaging type(s)	*Specify: functional, structural, diffusion, perfusion.*
Field strength	*Specify in Tesla*
Sequence & imaging parameters	*Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.*
Area of acquisition	*State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.*

Diffusion MRI   ☐ Used   ☐ Not used

Preprocessing

Preprocessing software	*Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).*
Normalization	*If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.*
Normalization template	*Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.*
Noise and artifact removal	*Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).*
Volume censoring	*Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.*

Statistical modeling & inference

Model type and settings	*Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).*
Effect(s) tested	*Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.*

Specify type of analysis: ☐ Whole brain ☐ ROI-based ☐ Both

Statistic type for inference (See Eklund et al. 2016)	*Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.*
Correction	*Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).*

Models & analysis

n/a	Involved in the study
☐	☐ Functional and/or effective connectivity
☐	☐ Graph analysis
☐	☐ Multivariate modeling or predictive analysis

Functional and/or effective connectivity	*Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).*
Graph analysis	*Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).*
Multivariate modeling and predictive analysis	*Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.*